Welcome to our dedicated page for Qiagen SEC filings (Ticker: QGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
QIAGEN N.V. filings document the reporting of a Netherlands-based foreign private issuer with common shares traded under QGEN. Its Form 20-F and Form 6-K disclosures cover audited annual financial statements, U.S. GAAP quarterly reports, operating and financial review, market-risk disclosures, legal proceedings, risk factors and the use of adjusted non-GAAP measures.
The filing record also includes exhibits and current reports tied to QIAGEN’s molecular diagnostics and life sciences portfolio, including sample technologies, QuantiFERON, QIAstat-Dx, QIAcuity and QIAGEN Digital Insights. Other disclosures address capital-structure actions such as a synthetic share repurchase and reverse stock split, material agreements, governance matters, exchange-listing registration notices and shareholder-facing corporate updates.
QIAGEN N.V. reported U.S. GAAP results for the quarter ended March 31, 2026. Net sales were $492.3 million, slightly above $483.5 million a year earlier, driven mainly by consumables. Net income fell to $68.0 million from $90.8 million, with diluted EPS at $0.33 versus $0.41.
Higher operating expenses, including $32.2 million of restructuring, acquisition, integration and other costs, reduced income from operations to $84.4 million from $115.3 million. Operating cash flow was $100.6 million, down from $139.7 million, while cash and cash equivalents declined to $646.3 million.
In January 2026, QIAGEN completed a $496.7 million synthetic share repurchase via capital repayment and reverse split, reducing outstanding shares by 10.9 million, or 5.0%. Long-term debt remained substantial at $1.65 billion, mainly convertible notes and German private placements.
QIAGEN N.V. reported Q1 2026 results showing modest sales growth but weaker earnings and a lower outlook. Net sales were $492 million, up 2% reported but down 1% at constant exchange rates. GAAP net income fell to $68 million, with diluted EPS declining to $0.33 from $0.41.
Adjusted diluted EPS was $0.54, slightly below $0.55 a year earlier, with an adjusted operating margin of 27.4% versus 29.8%. Growth pillars such as Sample technologies, QIAcuity and QIAGEN Digital Insights expanded, but QuantiFERON sales declined 5% at constant exchange rates due to sharply lower immigration testing demand.
Free cash flow dropped to $53.7 million from $95.8 million as operating cash flow declined and capital investments increased. QIAGEN cut its full-year 2026 guidance to 1–2% net sales growth at constant exchange rates and at least $2.43 adjusted diluted EPS, down from prior targets of at least 5% CER sales growth and at least $2.50 EPS.
QIAGEN N.V. released preliminary Q1 2026 results and cut its full-year 2026 outlook. Preliminary net sales were $492 million, up 2% reported but down 1% at constant exchange rates, below the prior goal for at least 1% CER growth. Adjusted diluted EPS are expected at $0.54, in line with the outlook, reflecting continued profitability.
The company’s growth pillars performed well: Sample technologies grew 9% CER to $170 million, QIAcuity digital PCR delivered double-digit CER gains, and QIAGEN Digital Insights posted solid single-digit growth. However, QuantiFERON sales fell 5% CER to $113 million, mainly from a sharp drop in immigration testing demand, and U.S. Life Sciences customers remained cautious.
QIAGEN now targets full-year 2026 net sales growth of about 1–2% CER instead of at least 5% CER, and adjusted diluted EPS of at least $2.43 CER, down from at least $2.50 CER. Management expects stronger trends in the second half of 2026 as portfolio headwinds ease and new products, including the Parse acquisition, contribute more.
QIAGEN N.V. reports 2025 net sales of $2,090.0 million, up from $1,978.2 million in 2024, driven mainly by consumables and related revenues, which made up 90% of sales. Instruments contributed the remaining 10%.
The Americas generated $1,086.5 million of net sales, with Europe, Middle East and Africa at $712.8 million and Asia Pacific, Japan and Rest of World at $290.7 million. As of December 31, 2025, the company had 5,654 employees and 216,920,735 outstanding common shares.
QIAGEN focuses on five growth pillars, including QIAcuity digital PCR, QIAstat‑Dx syndromic testing, QuantiFERON and its Digital Insights bioinformatics portfolio, aiming to grow pillar sales from $1.5 billion in 2025 to about $2 billion by 2028. The company serves more than 500,000 customers in molecular diagnostics and Life Sciences across over 160 countries, emphasizes ESG integration, and highlights detailed enterprise risk management around competition, supply chain, leadership succession and cyber security.
Wellington Management Group and affiliates report a 6.5% beneficial ownership stake in Qiagen N.V. common stock on Schedule 13G/A (Amendment No. 3). The group reports beneficial ownership of 14,137,799 shares as of the event date, with all voting and dispositive power held on a shared basis.
Within the complex, Wellington Management Company LLP reports shared voting power over 12,155,318 shares and shared dispositive power over 12,416,628 shares, representing 5.7% of the class. The filing states that the securities are owned of record by clients of Wellington investment advisers and are held in the ordinary course of business, without the purpose or effect of changing or influencing control of Qiagen.
BlackRock, Inc. reports owning 20,678,987 shares of QIAGEN N.V. common stock, representing 10.0% of the class as of January 31, 2026. BlackRock has sole voting power over 19,575,569 shares and sole dispositive power over the full 20,678,987 shares.
The filing states that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of QIAGEN. Various underlying clients have rights to dividends or sale proceeds, but no single client holds more than five percent of the outstanding common shares.
QIAGEN N.V. reported Q4 2025 and full-year 2025 results that modestly exceeded its own outlook and set guidance for 2026. Q4 net sales were $540 million, up 4% (1% at constant exchange rates), with adjusted diluted EPS of $0.62, ahead of guidance of about $0.60 CER.
For 2025, net sales reached $2.09 billion, up 6% (5% CER), at the high end of its 4–5% CER growth outlook. Adjusted diluted EPS was $2.40 CER, above the about $2.38 CER target, and the adjusted operating margin improved to 29.5% despite tariff and currency headwinds.
The company’s growth pillars generated $1.49 billion CER in 2025 sales with 8% CER growth, and it returned more than $1.1 billion to shareholders via synthetic share repurchases and a new cash dividend. For 2026, QIAGEN targets at least 5% CER sales growth, about $1.64 billion CER from growth pillars and adjusted diluted EPS of at least $2.50 CER.
QIAGEN N.V. is having its common shares removed from listing and registration on the New York Stock Exchange. The filing states that the Exchange has followed its own rules to strike this class of securities, and that the company has followed Exchange procedures and regulatory requirements for a voluntary withdrawal from listing and registration. This means QIAGEN’s common shares will no longer trade on the NYSE once the delisting process is effective, and trading would need to occur on other markets or venues if available.
QIAGEN N.V. submitted a Form 6-K noting that it has issued a press release with details on completing a synthetic share repurchase plan. This plan combines a direct capital repayment to shareholders with a reverse stock split, which together are intended to adjust the company’s share structure while returning capital.
The press release, dated December 18, 2025, is included as Exhibit 99.1 and is incorporated by reference, meaning the detailed terms of the synthetic share repurchase and reverse stock split are provided in that accompanying document.